David J Madrid1, Manjula Santhanakrishnan2, Jingchun Liu2, David R Gibb2, Dong Liu2, Prabitha Natarajan2, Daniel Beitler2, Zhimin Shi2,3, Chunyan Mo2,4, Christopher A Tormey2,5, Seema R Patel6, Sean R Stowell6, Jeanne E Hendrickson1,2. 1. Yale University School of Medicine, Department of Pediatrics, New Haven, CT, Unites States of America. 2. Yale University School of Medicine, Department of Laboratory Medicine, New Haven, CT, Unites States of America. 3. Nanfang Hospital of Southern Medical University, Department of Blood Transfusion, Guangzhou, Guangdong, China. 4. Institute of Clinical Transfusion, Guangzhou Blood Centre, Guangzhou, China. 5. VA Connecticut Healthcare System, Pathology and Laboratory Medicine Service, West Haven, CT, Unites States of America. 6. Emory University School of Medicine, Department of Pathology and Laboratory Medicine, Atlanta, GA, Unites States of America.
Abstract
BACKGROUND: Factors influencing the development of alloantibodies against blood group antigens on transfused red blood cells are poorly defined. We hypothesised that transfused platelets may act as a danger signal to recipients and affect humoral immune responses to transfused red blood cells. MATERIALS AND METHODS: Platelet-rich plasma prepared from wild-type C57BL/6 or CD40L knock-out donors was transfused into wild-type or CD40L knock-out recipients. Leucoreduced red blood cells from transgenic donors expressing high levels of the human KEL glycoprotein in an erythrocyte-specific manner (KELhi donors) were transfused after the platelets, and anti-KEL responses were measured longitudinally. In some experiments, recipients were treated with poly (I:C), monoclonal CD40L-blocking antibody, or CD4-depleting antibody prior to transfusion. RESULTS: Transfusion of wild-type C57BL/6 platelets or treatment with poly (I:C) prior to KELhi red blood cell transfusion led to an anti-KEL alloimmune response in wild-type recipients. Transfusion of platelets from wild-type but not CD40L knock-out donors prior to KELhi red blood cell transfusion led to an IgG anti-KEL alloimmune response in CD40L knock-out recipients; unexpectedly, transfusion of platelets from CD40L knock-out donors prior to KELhi red blood cell transfusion led to a robust anti-KEL alloimmune response in wild-type recipients. Recipient treatment with MR1 CD40L-blocking antibody or CD4-depleting antibody prevented KEL alloimmunisation altogether. DISCUSSION: Transfused platelets serve as an adjuvant in this T-dependent murine model of anti-KEL red blood cell alloimmunisation, with CD40/CD40L interactions being involved to some degree but with additional mechanisms also playing a role. These findings raise questions about the role that transfused or endogenous platelets may play in other innate/adaptive immune responses.
BACKGROUND: Factors influencing the development of alloantibodies against blood group antigens on transfused red blood cells are poorly defined. We hypothesised that transfused platelets may act as a danger signal to recipients and affect humoral immune responses to transfused red blood cells. MATERIALS AND METHODS: Platelet-rich plasma prepared from wild-type C57BL/6 or CD40L knock-out donors was transfused into wild-type or CD40L knock-out recipients. Leucoreduced red blood cells from transgenic donors expressing high levels of the human KEL glycoprotein in an erythrocyte-specific manner (KELhi donors) were transfused after the platelets, and anti-KEL responses were measured longitudinally. In some experiments, recipients were treated with poly (I:C), monoclonal CD40L-blocking antibody, or CD4-depleting antibody prior to transfusion. RESULTS: Transfusion of wild-type C57BL/6 platelets or treatment with poly (I:C) prior to KELhi red blood cell transfusion led to an anti-KEL alloimmune response in wild-type recipients. Transfusion of platelets from wild-type but not CD40L knock-out donors prior to KELhi red blood cell transfusion led to an IgG anti-KEL alloimmune response in CD40L knock-out recipients; unexpectedly, transfusion of platelets from CD40L knock-out donors prior to KELhi red blood cell transfusion led to a robust anti-KEL alloimmune response in wild-type recipients. Recipient treatment with MR1 CD40L-blocking antibody or CD4-depleting antibody prevented KEL alloimmunisation altogether. DISCUSSION: Transfused platelets serve as an adjuvant in this T-dependent murine model of anti-KEL red blood cell alloimmunisation, with CD40/CD40L interactions being involved to some degree but with additional mechanisms also playing a role. These findings raise questions about the role that transfused or endogenous platelets may play in other innate/adaptive immune responses.
Authors: Ross M Fasano; Garrett S Booth; Megan Miles; Liping Du; Tatsuki Koyama; Emily Riehm Meier; Naomi L C Luban Journal: Br J Haematol Date: 2014-09-26 Impact factor: 6.998
Authors: Sheritha P Lee; Kenneth I Ataga; Eugene P Orringer; David R Phillips; Leslie V Parise Journal: Arterioscler Thromb Vasc Biol Date: 2006-04-06 Impact factor: 8.311
Authors: Vicente Escamilla-Rivera; Jingchun Liu; David R Gibb; Manjula Santhanakrishnan; Dong Liu; James E Forsmo; Stephanie C Eisenbarth; Ellen F Foxman; Sean R Stowell; Chance John Luckey; James C Zimring; Krystalyn E Hudson; Jeanne E Hendrickson Journal: Blood Date: 2020-05-28 Impact factor: 25.476